| Market Capitalization (Millions $) |
467 |
| Shares
Outstanding (Millions) |
80 |
| Employees |
55 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-165 |
| Cash Flow (TTM) (Millions $) |
-8 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Atea Pharmaceuticals Inc, founded in 2014, is a biopharmaceutical company headquartered in Boston, Massachusetts, USA. The company is focused on discovering and developing novel antiviral therapeutics to treat infectious diseases. Their proprietary platform is based on the use of nucleotide prodrugs that target the viral RNA polymerase, a key enzyme essential for viral replication.
Atea Pharmaceuticals is particularly focused on developing antiviral therapies to combat RNA viruses like hepatitis C virus (HCV), respiratory syncytial virus (RSV), and most recently, the novel coronavirus (SARS CoV-2) responsible for COVID-19. The company has built a team of experienced scientists, biotech innovators, and clinical development experts with deep expertise in antiviral drug discovery and development.
Their lead drug candidate, AT-527, is being developed as an oral antiviral therapy for the treatment of influenza and COVID-19. In preclinical studies, AT-527 has demonstrated potent antiviral activity against a broad range of influenza strains and activity against SARS CoV-2 in vitro. The drug has received Fast Track designation from the US FDA for the treatment of COVID-19, and clinical trials are ongoing.
In addition to AT-527, Atea Pharmaceuticals has a pipeline of other antiviral candidates in preclinical development, including compounds for the treatment of RSV and HCV. The company has also established partnerships with leading academic institutions and biotech companies to collaborate on the development of antiviral therapies.
Atea Pharmaceuticals is backed by a group of leading venture capital firms, including Morningside Ventures, Cormorant Asset Management, and RA Capital Management. The company has raised over $500M in funding since its inception and has grown its team to more than 150 employees.
Overall, Atea Pharmaceuticals Inc is a rapidly growing biopharmaceutical company that is committed to developing innovative antiviral therapies to address unmet medical needs and improve patient outcomes.
Company Address: 225 Franklin Street Boston 2110 MA
Company Phone Number: 284-8891 Stock Exchange / Ticker: NASDAQ AVIR
|
2.88%